Compare AIR & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIR | AMRX |
|---|---|---|
| Founded | 1951 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.2B |
| IPO Year | 1994 | 2018 |
| Metric | AIR | AMRX |
|---|---|---|
| Price | $115.92 | $16.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $131.20 | $15.60 |
| AVG Volume (30 Days) | 326.7K | ★ 1.4M |
| Earning Date | 03-24-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1288.57 | 157.89 |
| EPS | ★ 4.86 | 0.37 |
| Revenue | N/A | N/A |
| Revenue This Year | $18.83 | $4.48 |
| Revenue Next Year | $10.93 | $7.13 |
| P/E Ratio | ★ $25.82 | $45.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $74.24 | $9.49 |
| 52 Week High | $154.00 | $19.26 |
| Indicator | AIR | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.99 | 44.87 |
| Support Level | $101.48 | $16.61 |
| Resistance Level | $121.05 | $18.19 |
| Average True Range (ATR) | 4.18 | 0.45 |
| MACD | -1.04 | -0.10 |
| Stochastic Oscillator | 0.72 | 30.82 |
AAR Corp offers a broad line of products and services to commercial and government aerospace customers and operates internationally. It is a diversified provider of services and products to the commercial aviation and government and defense markets, serving aircraft fleet operators, original equipment manufacturers, independent service providers, and domestic and foreign military customers. It operates through the Parts Supply, Repair, Engineering and Software, Government Solutions, and Legacy Commercial Programs segments. The Parts Supply segment mainly consists of new parts distribution and sales of used serviceable material, including aircraft, engine, and airframe parts and components (USM), and generates the maximum revenue. It generates the maximum revenue from North America.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.